Anti-IL-11 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Blocking a single swelling signal made mice live longer and healthier. It worked even when started in mice that were already old. No human ageing trial exists.
Evidence grade for Anti-IL-11: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 1 animal study, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 animal study, no human study
2 effects reported, 2 unwanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This means blocking IL-11, a signal molecule that rises with age and drives scarring and swelling. It is usually done with an antibody. In mice it made them live longer, even when started late. No drug of this kind is approved.
What people take it for
- Longer, healthier life, based on a mouse study.
- Scarring diseases, which is where early human testing is aimed.
What studies in people showed
Nobody has tested this for ageing in people. Drugs that block IL-11 are in early testing for scarring diseases. In mice, a 2024 study found blocking IL-11 made them live longer and healthier. It worked even when started in old mice. That is rare, which is why people noticed. No other lab has repeated it yet.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- IL-11 helps make blood cells. Blocking it long term has a risk nobody has measured.
- No product is available to anyone.
Where these come from: From the mouse study and drug history on this page. We have no user reports.
My bottom line
My opinion: an exciting mouse result, and that is all it is so far. Nothing to buy and nothing to take. Watch for other labs to repeat it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 1 citation on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Anti-IL-11?
Blocking a single swelling signal made mice live longer and healthier. It worked even when started in mice that were already old. No human ageing trial exists.
This is one of the more striking mouse results in recent ageing research. The detail that matters is when treatment started.
First, people: no human ageing trial has been run. Drugs that block IL-11 are in early human testing for scarring diseases, not for ageing.
Interleukin-11, or IL-11, is a signal molecule in the same family as IL-6. It rises with age and drives scarring and swelling. A 2024 Nature paper reported that blocking IL-11 made mice live longer and stay healthy longer. It helped even when treatment began in mice that were already old.
Most lifespan treatments have to start young. That limits their use for anyone already alive and ageing. A treatment that works late is a different matter, which is why this result drew the attention it did.
How does Anti-IL-11 work?
IL-11 works through a receptor made of two parts, IL-11RA and gp130. That switches on signals inside the cell called JAK, STAT3 and ERK. IL-11 drives scar making cells and scarring across organs, and the body makes more of it with age. Blocking it cuts scarring and swelling signals. In the mouse work, it also changed signals tied to metabolism and mTOR, which is one idea for how it extended life. Note that IL-11 has normal jobs too, including in making blood cells. So blocking it for life is not free of consequences.
What have studies in people found about Anti-IL-11?
None for ageing. Drugs that block IL-11 are in early testing for scarring diseases. No ageing or lifespan measure has been studied in people.
- No human trial has tested IL-11 blocking for ageing, healthy lifespan or lifespan.
- Early human testing targets scarring diseases, where IL-11's role is best known.
- Lab made IL-11 was itself an approved drug, used to raise low platelet counts after chemotherapy. So some effects of changing this signal in people are known, and they are not trivial.
- IL-11 plays a part in making blood cells. Blocking it for a long time carries a believable risk that nobody has measured.
What this does not tell you: Everything about the ageing claim is in mice. The late start benefit is the most interesting part. It is also the part most in need of repeating, because late start lifespan results often fail to hold up in other labs. Nothing here supports use in people, and no IL-11 blocking product is available.
The state of the research
This result is worth following for one reason. Almost every treatment that extends lifespan in mice has to start early in life. That makes it interesting to science and useless in practice for anyone already old. A treatment that works when started late could matter to a real person, and this is one of the few claims like that from a top journal.
The right doubt is about whether it repeats, not whether it makes sense. The Interventions Testing Program runs lifespan tests at several labs at once for exactly this reason. Single lab lifespan results, late start ones included, often fail to repeat at other sites. Its 2026 group found compounds that worked at one dose and not another. Until IL-11 blocking has been through something like that, treat it as a promising untested idea, not a proven one.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 1 animal study. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 1 source here is a study in people.
- Animal study · done in animals1100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2024.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Monoclonal antibody, roughly 150 kDa. Not a peptide.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not asserted. Depends on the specific antibody, and no figure for a human agent in this class was resolved in the sources loaded. Monoclonal antibodies generally clear over weeks.
No amino acid sequence is on file for Anti-IL-11, so none is drawn rather than guessed from a name.
The studies we cite
- Animal study2024Inhibition of IL-11 signalling extends mammalian healthspan and lifespan
In mice. Blocking IL-11 made mice live longer and stay healthy longer. It worked even when treatment started in mice that were already old. That late start is what sets it apart, since most lifespan treatments only work if started early.
Mouse work. Inhibiting interleukin-11 signalling extended both healthspan and lifespan, including when treatment began in already old animals. That late-start benefit is the feature that distinguishes it from most lifespan interventions, which must start early to work.
Common questions
Has Anti-IL-11 been tested in people?
Not in any study cited here. Blocking a single swelling signal made mice live longer and healthier. It worked even when started in mice that were already old. No human ageing trial exists.
What is the Anti-IL-11 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 animal study, no human study
Is Anti-IL-11 FDA-approved?
No drug that blocks IL-11 is approved for any use. A lab-made version of IL-11 itself, oprelvekin, was once an approved drug for low platelets. That is the opposite approach.
Did blocking IL-11 really extend lifespan?
In mice, in a 2024 Nature paper, yes. That includes when treatment started in mice that were already old. There is no human ageing data, and no other labs have repeated the lifespan result.
Why is the late start important?
Because most lifespan treatments in mice only work if started young. That makes them useless to anyone already ageing. Something that works late is the only kind that could become a treatment, instead of a lifelong plan begun in youth.
Can I get an anti-IL-11 drug?
No. Nothing in this group is approved for anything. Early human testing is aimed at scarring diseases, not ageing.
Is blocking an inflammatory cytokine safe long term?
Unknown. IL-11 has normal jobs, including in making blood cells. Lab made IL-11 was once used as a drug to raise platelet counts. Nobody has studied long term blocking in people.